` APLS (Apellis Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

APLS
vs
S&P 500

Over the past 12 months, APLS has underperformed S&P 500, delivering a return of -47% compared to the S&P 500's +13% growth.

Stocks Performance
APLS vs S&P 500

Loading
APLS
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
APLS vs S&P 500

Loading
APLS
S&P 500
Difference
www.alphaspread.com

Performance By Year
APLS vs S&P 500

Loading
APLS
S&P 500
Add Stock

Competitors Performance
Apellis Pharmaceuticals Inc vs Peers

S&P 500
APLS
ABBV
AMGN
GILD
VRTX
Add Stock

Apellis Pharmaceuticals Inc
Glance View

In the realm of biotechnology, Apellis Pharmaceuticals Inc. has carved out a niche by pioneering therapies that target the complement system, an integral part of the immune response. Founded in 2009, the company quickly honed in on the inhibition of C3, a protein central to the activation of the complement cascade, which can drive various diseases when dysregulated. Through its proprietary platform, Apellis has developed novel therapeutic candidates that aim to modulate the immune system from an entirely fresh angle. The company focuses on addressing serious medical conditions that currently have limited treatment options, such as age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH), by employing targeted therapies to reduce inflammation and improve patient outcomes. Apellis’s business strategy revolves around a model that not only aims to bring innovative treatments to market but also to establish partnerships that broaden the reach of its technology. The company's flagship drug, Empaveli, received FDA approval for PNH in 2021 and underscores its potential to capture larger market segments within rare disease treatment areas. By investing heavily in research and development, Apellis seeks to expand its pipeline while also collaborating with other firms to enhance its capabilities and share the risks and rewards associated with drug development. Revenue is generated primarily through sales of its approved therapies, as well as milestone payments and royalties from partnerships, setting Apellis on a path poised for growth if it continues to advance its clinical programs successfully.

APLS Intrinsic Value
65.12 USD
Undervaluation 70%
Intrinsic Value
Price
Back to Top